Case report: Bruton tyrosine kinase inhibitor as therapy for chronic lymphocytic leukemia infiltrating a kidney allograft

被引:0
|
作者
Stavart, Louis [1 ,2 ]
Halfon, Matthieu [1 ,2 ]
Dewarrat, Natacha [3 ]
Rotman, Samuel [4 ]
Golshayan, Dela [1 ,2 ,5 ]
机构
[1] Lausanne Univ Hosp CHUV, Transplantat Ctr, Lausanne, Switzerland
[2] Lausanne Univ Hosp CHUV, Transplantat Immunopathol Lab, Lausanne, Switzerland
[3] Lausanne Univ Hosp CHUV, Serv & Cent Lab Hematol, Lausanne, Switzerland
[4] Lausanne Univ Hosp CHUV, Inst Pathol, Lausanne, Switzerland
[5] Univ Lausanne UNIL, Fac Biol & Med, Lausanne, Switzerland
关键词
chronic lymphocytic leukemia; kidney transplantation; Bruton tyrosine kinase inhibitor; acute cellular rejection; case report; B-CELL LYMPHOCYTOSIS; TRANSPLANTATION; IBRUTINIB; LYMPHOMA; PATIENT; DONOR;
D O I
10.3389/fmed.2024.1451264
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The burden of chronic lymphocytic leukemia (CLL) in the prognosis of solid organ transplant (SOT) recipients seems non-negligible. Whether transplanting a patient with previous CLL is safe or what is the optimal monitoring and treatment management after transplantation is still unclear and only based on few case series and reports. Therefore, we aimed to contribute to this understanding by reporting the first documented case of a clinically significant CLL with biopsy-proven infiltration of the kidney allograft and its successful management with a Bruton tyrosine kinase inhibitor (BTKi). We then reviewed the related literature, with a focus on CLL and kidney transplantation. Our main message is that BTKi may represent a safe and effective intervention to prevent the hazardous patient and graft outcomes of CLL in SOT patients.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Non-Covalent Bruton's Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia
    Montoya, Skye
    Thompson, Meghan C. C.
    CANCERS, 2023, 15 (14)
  • [32] TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis
    Cherng, Hua-Jay J.
    Khwaja, Raamis
    Kanagal-Shamanna, Rashmi
    Tang, Guilin
    Burger, Jan
    Thompson, Philip
    Ferrajoli, Alessandra
    Estrov, Zeev
    Sasaki, Koji
    Sampath, Deepa
    Wang, Xuemei
    Kantarjian, Hagop
    Keating, Michael
    Wierda, William G.
    Jain, Nitin
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (08) : 1005 - 1012
  • [33] Tyrosine kinase inhibitor resistance in pediatric chronic myeloid leukemia: a case report
    Aisyi, Mururul
    Syarif, Ayu Hutami
    Asih, Nur
    Kosasih, Agus
    MEDICAL JOURNAL OF INDONESIA, 2020, 29 (04) : 427 - 430
  • [34] Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes
    Cervantes-Gomez, F.
    Patel, V. Kumar
    Bose, P.
    Keating, M. J.
    Gandhi, V.
    LEUKEMIA, 2016, 30 (08) : 1803 - 1804
  • [35] Pericardial effusion in patients with chronic lymphocytic leukemia treated with Bruton's tyrosine kinase inhibitors
    Hofstetter, Liron
    Shimoni, Shai
    Raanani, Pia
    Itchaki, Gilad
    LEUKEMIA & LYMPHOMA, 2023, 64 : S59 - S60
  • [36] The impact of Bruton's tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia
    Yang, Shenmiao
    Wei, Rong
    Shi, Hongxia
    Wang, Yazhe
    Lai, Yueyun
    Zhao, Xiaosu
    Lu, Jin
    Schmitz, Norbert
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [37] Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia
    Pleyer, Christopher
    Wiestner, Adrian
    Sun, Clare
    LEUKEMIA & LYMPHOMA, 2018, 59 (12) : 2792 - 2800
  • [38] Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise
    Foluso, Ogunleye
    Glick, Alexander
    Stender, Michael
    Jaiyesimi, Ishmael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (02): : 63 - 69
  • [39] Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma
    Wolska-Washer, Anna
    Robak, Pawel
    Witkowska, Magdalena
    Robak, Tadeusz
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2024, 20 (04) : 207 - 224
  • [40] The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia
    Herman, Sarah E. M.
    Montraveta, Arnau
    Niemann, Carsten U.
    Mora-Jensen, Helena
    Gulrajani, Michael
    Krantz, Fanny
    Harrington, Bonnie K.
    Covey, Todd
    Lannutti, Brian J.
    Izumi, Raquel
    Ulrich, Roger G.
    Byrd, John C.
    Wiestner, Adrian
    Johnson, Amy J.
    Woyach, Jennifer A.
    BLOOD, 2015, 126 (23)